There are 413 resources available
Comparative prognostic studies from real-world data: Real or not real?
Presenter: Peter A. Fasching
Session: Utility of real-world data
Resources:
Slides
Webcast
Impact of molecular heterogeneity on treatment selection
Presenter: Kyong Hwa Park
Session: Novel endocrine therapies
Resources:
Slides
Webcast
PARP inhibition in early breast cancer: What have we learned and how can we move forward?
Presenter: Andrew Tutt
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Novel endocrine therapies
Resources:
Webcast
ESMO GROW: Methodological guidance for reporting oncology real-world evidence
Presenter: Suzette Delaloge
Session: Utility of real-world data
Resources:
Slides
Webcast
PARP inhibitor combination strategies in early breast cancer: Rationale and results to date
Presenter: Kevin Punie
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Utility of real-world data
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Webcast
Introduction and first vote
Presenter: Peter Dubsky
Session: Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions
Resources:
Slides
Webcast
Yes
Presenter: Sabine Linn
Session: Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions
Resources:
Slides
Webcast